Evidence map›Paper›PMID 35429500›Full record

ArticleThe Journal of biological chemistry2022

Assembly of nuclear dimers of PI3K regulatory subunits is regulated by the Cdc42-activated tyrosine kinase ACK.

Natasha S Clayton, Millie Fox, Jose J Vicenté-Garcia, Courtney M Schroeder, Trevor D Littlewood, Jonathon I Wilde, Kadalmani Krishnan, Murray J B Brown, Claire Crafter, Helen R Mott and 1 more

Open access · goldAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Natasha S ClaytonDepartment of Biochemistry, University of Cambridge, Cambridge, United Kingdom.
Millie FoxDepartment of Biochemistry, University of Cambridge, Cambridge, United Kingdom.
Jose J Vicenté-GarciaDepartment of Biochemistry, University of Cambridge, Cambridge, United Kingdom.
Courtney M SchroederDepartment of Biochemistry, University of Cambridge, Cambridge, United Kingdom.
Trevor D LittlewoodDepartment of Biochemistry, University of Cambridge, Cambridge, United Kingdom.
Jonathon I WildeGlaxoSmithKline Medicines Research Centre, Screening and Compound Profiling, Stevenage, Herts, United Kingdom.
Kadalmani KrishnanDepartment of Biochemistry, University of Cambridge, Cambridge, United Kingdom.
Murray J B BrownGlaxoSmithKline Medicines Research Centre, Screening and Compound Profiling, Stevenage, Herts, United Kingdom.
Claire CrafterBioscience, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
Helen R MottDepartment of Biochemistry, University of Cambridge, Cambridge, United Kingdom. Electronic address: hrm28@cam.ac.uk.
Darerca OwenDepartment of Biochemistry, University of Cambridge, Cambridge, United Kingdom. Electronic address: do202@cam.ac.uk.
University of Cambridge · GBGlaxoSmithKline (United Kingdom) · GBAstraZeneca (United Kingdom) · GB

Funding

Biotechnology and Biological Sciences Research Council BB/A517685/1Biotechnology and Biological Sciences Research Council BB/F017464/1Cancer Research UK 19013Medical Research Council MR/N018354/1
6 · The paper itself

Abstract

Activated Cdc42-associated kinase (ACK) is an oncogenic nonreceptor tyrosine kinase associated with poor prognosis in several human cancers. ACK promotes proliferation, in part by contributing to the activation of Akt, the major effector of class 1A phosphoinositide 3-kinases (PI3Ks), which transduce signals via membrane phosphoinositol lipids. We now show that ACK also interacts with other key components of class 1A PI3K signaling, the PI3K regulatory subunits. We demonstrate ACK binds to all five PI3K regulatory subunit isoforms and directly phosphorylates p85α, p85β, p50α, and p55α on Tyr607 (or analogous residues). We found that phosphorylation of p85β promotes cell proliferation in HEK293T cells. We demonstrate that ACK interacts with p85α exclusively in nuclear-enriched cell fractions, where p85α phosphorylated at Tyr607 (pTyr607) also resides, and identify an interaction between pTyr607 and the N-terminal SH2 domain that supports dimerization of the regulatory subunits. We infer from this that ACK targets p110-independent p85 and further postulate that these regulatory subunit dimers undertake novel nuclear functions underpinning ACK activity. We conclude that these dimers represent a previously undescribed mode of regulation for the class1A PI3K regulatory subunits and potentially reveal additional avenues for therapeutic intervention.

Indexed as

Phosphatidylinositol 3-KinasesProtein-Tyrosine KinasesCell NucleusHEK293 CellsHumansPhosphorylationProtein MultimerizationSignal TransductionPhosphatidylinositol 3-KinasesProtein-Tyrosine KinasesTNK2 protein, humanactivated Cdc42 kinasecancerCdc42nuclear signalingp110-independent p85p85 dimersPI3Kinaseprotein degradationprotein phosphorylationtyrosine kinase

Identifiers

PMID35429500
PMCPMC9127371
OpenAlexW4224010140

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.